Literature DB >> 10567743

Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations.

Z Shen1, Q Zhang, S Wei, T Nagai.   

Abstract

In vitro biodegradation of insulin in lung cytosol and subcellular pellets of normal and diabetic rats was investigated. Rat lung was homogenized and subcellular fractions were isolated by ultracentrifugation. Degradations of [125I]-insulin after incubation with lung cytosol or subcellular pellets was determined using the trichloroacetic acid method. The results show that insulin is highly degraded in cytosol and subcellular pellets. Cytosolic insulin degradation was strongly inhibited by bacitracin or sodium cholate. The degradation of insulin in the lung cytosol from diabetic rats was significantly less than from normal rat. The lung protease activity reached a maximum at pH 7.4. Enzyme inhibitors like bacitracin and sodium cholate noticeably enhanced the relative pharmacological bioavailability of insulin when given intratracheally with insulin to normal rats. Acidic insulin solutions (pH 3.0) had more pronounced hypoglycaemic effects than neutrol solution (pH 7.0). These in vitro and in vivo results suggest that the proteolytic enzymes in the lung limit pulmonary delivery of insulin. The coadministration of protease inhibitors would be a useful approach for improving the pulmonary absorption of insulin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567743     DOI: 10.1016/s0378-5173(99)00295-1

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

2.  Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.

Authors:  Mathangi Gopalakrishnan; Sandra Suarez; Anthony J Hickey; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 3.  Clinical pharmacokinetics and pharmacodynamics of inhaled insulin.

Authors:  John S Patton; Julie G Bukar; Michael A Eldon
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Enhancement of insulin transport across primary rat alveolar epithelial cell monolayers by endogenous cellular factor(s).

Authors:  Rana Bahhady; Kwang-Jin Kim; Zea Borok; Edward D Crandall; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2007-04-19       Impact factor: 4.200

Review 5.  A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.

Authors:  Nishat Fatima; Vichitra Kaushik; Amjad Ayoub
Journal:  Iran J Med Sci       Date:  2021-05

Review 6.  The lung as a route for systemic delivery of therapeutic proteins and peptides.

Authors:  R U Agu; M I Ugwoke; M Armand; R Kinget; N Verbeke
Journal:  Respir Res       Date:  2001-04-12

Review 7.  Insulin and the lung: connecting asthma and metabolic syndrome.

Authors:  Suchita Singh; Y S Prakash; Allan Linneberg; Anurag Agrawal
Journal:  J Allergy (Cairo)       Date:  2013-09-24

8.  Preclinical Development of Orally Inhaled Drugs (OIDs)-Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models?

Authors:  Dania Movia; Adriele Prina-Mello
Journal:  Animals (Basel)       Date:  2020-07-24       Impact factor: 2.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.